J2690Procainamide hcl injection
Published CMS Medicare Part B payment-limit context for J2690, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$295.361
per 1 GM · Medicare Part B
Up 37.5%from $214.811 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$596.8909$132.2061
2024-Q4: $546.066; 2025-Q1: $183.031; 2025-Q2: $284.337; 2025-Q3: $194.316; 2025-Q4: $294.691; 2026-Q1: $344.53; 2026-Q2: $214.811; 2026-Q3: $295.361
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Procainamide Hydrochloride ingredient family (FDA data as of August 20, 2026).
Procainamide Hcl
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.